GLP-1 drugs, including Mounjaro, Wegovy, and Ozempic, have become increasingly popular in India for their ability to promote significant weight loss. Originally developed to treat type 2 diabetes, these medications mimic gut hormones that regulate appetite and blood sugar, helping patients reduce hunger, slow digestion, and lose weight effectively over months. Their use has expanded beyond diabetes care to include obesity-related conditions like PCOS and fertility challenges.
Stand-up comedian Aishwarya Mohanraj recently shared her experience of losing 22 kg in six months using these drugs, highlighting their potential impact. However, the high cost—up to Rs 13,125 per month for Mounjaro—remains a barrier for long-term use.
Experts such as Dr Anoop Misra, Dr Ambrish Mithal, and Dr V Mohan emphasise that GLP-1 therapy is not a cosmetic shortcut but a medical intervention. Candidates are usually adults with a BMI of 30 or above, or 27 and above with comorbidities, after thorough metabolic evaluation. Screening for gallbladder health, liver function, pregnancy, and body composition is crucial before starting therapy.
Medical supervision ensures proper dosage, gradual titration, and safe discontinuation to minimise side effects and the risk of rebound weight gain. While GLP-1 drugs can be transformative, self-prescription or abrupt stopping can be dangerous. The key takeaway: these medications are powerful tools for metabolic health but must be used responsibly under the guidance of qualified healthcare professionals.
